Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 59-63

  Yannaki, Evangelia ^a   Stamatoyannopoulos, George ^b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

G CSF; mobilization; sickle cell disease; thalassemia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PLERIXAFOR;

BETA THALASSEMIA; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; GENE THERAPY; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; LOW DRUG DOSE; RISK REDUCTION; SICKLE CELL ANEMIA; SPLENOMEGALY; STEM CELL MOBILIZATION; THALASSEMIA MAJOR;

EID: 77955906593     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05576.x     Document Type: Conference Paper

References (40)

1. Papayannopoulou, T. &D. Scadden. 2008. Stem-cell ecology and stem cells in motion. Blood 111: 3923-3930.
2. Gratwohl, A, H. Baldomero, K. Frauendorfer & A. Urbano- Ispizua. 2006. EBMT activity survey 2004 and changes in disease indication over the past 15 years: Joint Accreditation Committee, International Society for Cellular Therapy; European Group for Blood andMarrow Transplantation. Bone Marrow Transplant . 37: 1069-1085.
3. To, L.B., D.N. Haylock, P.J. Simmons & C.A. Juttner. 1997. The biology and clinical uses of blood stem cells. Blood 89: 2233-2258.
4. Welte, K., E. Platzer, L. Lu, et al. 1985. Purification and biochemical characterization of humanpluripotent hematopoietic colony-stimulating factor. Proc. Natl. Acad. Sci. USA 82: 1526-1530. (Pubitemid 15120576)
5. Horowitz, M.M. & D.L. Confer. 2005. Evaluation of hematopoietic stemcell donors.Hematol. Am. Soc.Hematol. Educ. Program. 469-475.
6. Dunbar, C.E., N.E. Seidel, S. Doren, et al. 1996. Improved retroviral gene transfer into murine and rhesus peripheral blood or bonemarrowrepopulating cells primedinvivowith stem cell factor and granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. USA 93: 11871-21176
7. Horn, P.A., K.A. Keyser, L.J. Peterson, et al. 2004. Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 103: 37103716.
8. Thomasson, B., L. Peterson, J. Thompson, et al. 2003. Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stemcells in dogs. Hum.Gene Ther. 14: 1683-1686.
9. Platzbecker, U., G. Prange-Krex, M. Bornhäuser, et al. 2001. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 41: 184-189.
10. Stiff, P.J., W. Bensinger, M.H. Abidi, et al. 2009. Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors. Biol. Blood Marrow Transplant . 15: 827-834.
11. Falzetti, F., F. Aversa, O. Minelli & A. Tabilio. 1999. Spontaneous rupture of spleen during peripheral blood stem cell mobilisation in a healthy donor. Lancet 353: 555.
12. Becker, P.S., M. Wagle, S. Matous, et al. 1997. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF) occurrence in allogeneic donor of peripheral blood stem cells. Biol. Blood Marrow Transplant . 3: 45-49.
13. Brown, S.L. & D.C. Dale. 1997. Spontaneous rupture following administration of of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol. Blood Marrow Transplant. 3: 45-49.
14. Balaguer, H., A. Galmes, G. Ventayol, et al. 2004. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 44: 1260-1261.
15. Dincer, A.P., J. Gottschall & D.A. Margolis. 2004. Splenic rupture in a prarental donor undergoing peripheral blood progenitor cell mobilization. J. Pediatr. Hematol. Oncol. 26: 761-763.
16. Fukumoto, Y.,T.Miyamoto, T. Okamura, et al. 1997. Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acutemyelogenous leukaemia. Br. J. Haematol. 97: 666-668.
17. Lindemann, A. & B. Rumberger. 1993. Vascular complications inpatients treatedwith granulocyte colony-stimulating factor (G-CSF). Eur. J. Cancer. 29A: 2338-2339.
18. Anderlini, P., J.D. Rizzo, M.L. Nugent, et al.; IBMTR Statistical Center of the International Bone Marrow Transplant Registry, Medical College of Wisconcin, Milwaukee, WI, USA; EBMT, Kiel, Germany. 2001. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant . 27: 689-692.
19. Pawliuk, R., K.A. Westerman, M.E. Fabry, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
20. May, C., S. Rivella, J. Callegari, et al. 2000. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406: 82-86.
21. Imren, S., E. Payen, K.A.Westerman, et al. 2002. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 99: 14380-14385.
22. Rivella, S., C. May, A. Chadburn, et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviralmediatedhumanbeta- globin gene transfer. Blood 101: 2932-2939.
23. Puthenveetil, G., J. Scholes, D. Carbonell, et al. 2004. Successful correction of the humanbeta-thalassemiaMajor phenotype using a lentiviral vector. Blood 104: 3445-3453.
24. Miccio, A., R. Cesari, F. Lotti, et al. 2008. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc. Natl. Acad. Sci. USA 105: 10547-10552.
25. Bank,A., R.Dorazio&P.Leboulch. 2005.Aphase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann. N.Y. Acad. Sci. 1054: 308-316.
26. Abboud, M., J. Laver & C.A. Blau. 1998. Granulocytosis causing sickle-cell crisis. Lancet 351: 959.
27. Adler, B.K., D.E. Salzman, M.H. Carabasi, et al. 2001. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97: 3313-3314.
28. Grigg, A.P. 2001. Granulocyte colony-stimulating factorinduced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 97: 3998-3999.
29. Kamble, R.T., C.K. Tin-U & G. Carrum. 2006. Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 37: 1065-1066.
30. Rosenbaum, C., D. Peace, E. Rich & K. Van Besien. 2008. Granulocyte colony-stimulating factor-based stem cell mobilization in patientswith sickle cell disease. Biol. BloodMarrow Transplant . 14: 719-723.
31. Fitzhugh, C.D., M.M. Hsieh, C.D. Bolan, et al. 2009. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy 11: 464-471.
32. Lamming, C.E., L. Augustin, M. Blackstad, et al. 2003. Spontaneous circulation ofmyeloid-lymphoid-initiating cells and SCID-repopulating cells in sickle cell crisis. J. Clin. Invest. 111: 811-819.
33. Richard, R.E.,N. Siritanaratkul, E. Jonlin, et al. 2005.Collection of blood stem cells frompatientswith sickle cell anemia. Blood Cells Mol. Dis. 35: 384-388.
34. Hal, E. Broxmeyer, Christie M. Orschell, D. Wade Clapp, et al. 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201: 1307-1318.
35. Liles,W.C., H.E. Broxmeyer, E.Rodger, et al. 2003.Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728-2730.
36. Devine, S.M., R. Vij, M. Rettig, et al. 2008. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112: 990-998.
37. Li, K., A. Wong, C.K. Li, et al. 1999. Granulocyte colonystimulating factor-mobilized peripheral blood stem cells in β-thalassemia patients: kinetics of mobilization and composition of apheresis product. Exp. Hematol. 27: 526-532.
38. Yannaki, E., N. Psatha, E. Athanasiou, et al. 2009. Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia. Hum Gene Ther. 21: 299-310.
39. Cappellini, M.D., L. Robbiolo, B.M. Bottasso, et al. 2000. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br. J. Haematol. 111: 467-473.
40. Saxon, B.R., D. Rees & N.F. Olivieri. 1998. Regression of extramedullary hemopoiesis and augmentation of fetal hemoglobin concentration during hydroxyurea therapy in β-thalassemia. Br. J. Haematol. 101: 416-419.